Peginesatide

CHEMBL2107866 Phase 4 Onaylandı Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A PEGylated synthetic peptide that activates the erythropoietin receptor to stimulate red blood cell production, used to treat anemia in adult patients on dialysis. It was recalled from the market following reports of serious allergic reactions.

Terapötik Alanlar

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A PEGylated synthetic peptide that activates the erythropoietin receptor to stimulate red blood cell production, used to treat anemia in adult patients on dialysis. It was recalled from the market following reports of serious allergic reactions.

Yes, Peginesatide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107866. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.